Survival rates are lower for patients with high-risk melanoma with mutations
the ONA take:
Researchers from UNC Lineberger Comprehensive Cancer Center analyzed melanoma samples to determine if tumors with the BRAF or NRAS gene mutations indicated poorer prognosis for those patients.
This study was conducted before new treatments for melanoma were approved, including the first BRAF inhibitor approved in 2011. Therefore, the connection between the mutations and outcomes were determined without the influence of the new drugs.
In this study, 912 patients with melanoma were followed for 7 years. All the patients were enrolled through the GEM study, and their diagnoses were made in 2000.
Thirteen percent of patients had tumors with NRAS mutations, 30% had BRAF mutations, and 57% had neither mutation. The researchers found that 73% of patients with high-risk, NRAS-mutated tumors and 71% of patients with high-risk, BRAF-mutated tumors survived 5 years, compared with 82% of high-risk tumors with neither mutation.
Overall, no statistical difference was seen in 5-year survival for people with NRAS or BRAF mutations compared with those people who had no mutation.
However, 5-year survival was lower in people with high-risk tumors with mutations.
No statistical difference was seen in 5-year survival for melanoma patients with NRAS or BRAF mutations.
- Immunotherapy May Benefit Some Patients with Papillary Thyroid Carcinoma
- Screening Recommendations for Children with Common Cancer Predisposition Syndromes
- Significance of Prostate Cancer Treatment-Related Factors Differ in Black, White Men
- New Study Questions Standard Dosage for Treating Metastatic Non-Small Cell Lung Cancer
- Superior Tolerability, Efficacy With Alectinib in Treatment-Naïve ALK-poistive NSCLC
- Survivorship Care Plans: Providing A Blueprint for Health Care After Cancer
- Cancer Recurrence Fear Reduced by Novel Psychological Intervention
- Multifaceted Role of the Nurse Navigator Includes Palliative, Supportive Care
- Patient Navigators Found to Boost Lung Cancer Screening Rates
- Lack of Transfusion Services a Barrier to Hospice Care for Patients With Blood Cancers
- Aspirin Use May Lower Breast Cancer Risk in Women with Diabetes
- Ethnic Differences, Cultural Barriers Negatively Impact Mammography Follow-up Among Asian Ethnic Groups
- Study Questions Safety of E-cigarettes vs Regular Tobacco Cigarettes
- Changes in Pulmonary Function Tests in Breast Carcinoma Patients Treated With Locoregional Post-mastectomy Radiotherapy: Results of a Pilot Study
- Increases in Liver Cancer Incidence Influenced by Higher Rates of Comorbidities
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|